
Current Price | $0.60 | Mkt Cap | $9.8M |
---|---|---|---|
Open | $0.60 | P/E Ratio | -0.19 |
Prev. Close | $0.60 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.56 - $0.67 | Volume | 417,991 |
52-Wk Range | $0.55 - $4.86 | Avg. Daily Vol. | 250,493 |
Current Price | $0.60 | Mkt Cap | $9.8M |
---|---|---|---|
Open | $0.60 | P/E Ratio | -0.19 |
Prev. Close | $0.60 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.56 - $0.67 | Volume | 417,991 |
52-Wk Range | $0.55 - $4.86 | Avg. Daily Vol. | 250,493 |
The best Bull and Bear pitches based on recency and number of recommendations.
It looks like my reservations about AcelRx when the share price was 7 a few weeks ago were right, although the stock went on to a new six-month high over 9 just before the Sword of Damocles dropped. People or institutions who were buying AcelRx in… More
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about ACRX.
Recs
Incredible Growth Story: AcelRx Pharmaceuticals, Inc. (ACRX)
By
Misty Lee -
January 17, 2019
B. Riley FBR rated the AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)’s stock as a Buy in a research note published on Tuesday, October 23rd, 2018 and posted a $9 price target on the common stock of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Other Wall Street experts have also recently posted reports on these shares. RBC Capital Mkts gave the stock an Outperform rating, while setting a price target at $5 in a research note from Friday, October 13th, 2017. Jefferies rated the stock as a Hold in a research note dated Friday, October 13th, 2017.
At the moment, there are a total of 8 analysts who cover AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) stock. Among that group, 2 of them gave BUY ratings, 4 of them rated the stock as OUTPERFORM, 2 recommended it as HOLD, 0 set the rating at UNDERPERFORM and 0 rated it as a SELL. Looking at the big picture from the data above, the average analyst rating for AcelRx Pharmaceuticals, Inc. is 2.00.
The company, which is valued at $181.80M, last published its earnings results on Friday, 11/02/2018 for the quarter that ended in Sep-18. The business posted revenue of $0.38 million for the three-month period, below -$0.53 million, compared to analysts’ forecasts of $0.91 million with a surprise factor of 58.46%. The organization posted -$0.21 earnings per share (EPS) for the three-month period, surpassing the Thomson Reuter’s analyst consensus estimate of -$0.21 amounting to a surprise factor of -1.20%.
At times, the stock market can get highly confusing – even for some of the most experienced traders. Even when the result is what you had expected, the market might suddenly decide to make an opposing movement. This can spark a great deal of doubt and second-guessing. Keeping tabs on historical price performance, as well as both long-term and short-term trends, can be very useful. Over the past 7 days, AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) stock has decreased in price by 14.55%. Looking backwards over the past quarter, these shares have fell -45.22%. Turning to look at the last 6 months, this stock has dropped 24.19% to its price. Since the beginning of the calendar year, this stock has moved up by 9.30%.
Now let’s examine some potential support and resistance levels for this particular stock. Following a recent spotcheck, the public organization AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has been observed as trading -53.47% away from its 90-day high price. Taking a look at the other side of things, this stock has been trading +18.09% away from its 90-day low. Moving to a broader perspective, this stock has recently been trading -53.47% away from its 52-week high and +42.42% away from its 52-week low price.
Recs
Great new pain Mgmt platform
Recs
TP 8
Find the members with the highest scoring picks in ACRX.
brian3305 (< 20) Score: +285.55
The Score Leader is the player with the highest score across all their picks in ACRX.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
brian3305 | < 20 | 10/23/2012 |
![]() |
3M | $3.14 | -80.86% | +204.69% | +285.55 | 0 Comment | |
SaiyanBroker | 88.65 | 3/15/2013 |
![]() |
NS | $4.65 | -87.08% | +177.45% | +264.53 | 0 Comment | |
OriginalBarnacle | 70.61 |
|
![]() |
1Y | $9.10 | -93.40% | +163.83% | +257.22 | 0 Comment | |
jackbot | 97.52 | 7/28/2014 |
![]() |
5Y | $6.45 | -90.68% | +118.31% | +208.99 | 0 Comment | |
jasonrivera | 27.60 | 1/13/2016 |
![]() |
5Y | $3.05 | -80.29% | +128.40% | +208.69 | 0 Comment | |
![]() |
gpierson128 | 77.33 | 1/14/2019 |
![]() |
5Y | $2.61 | -76.97% | +68.27% | +145.25 | 0 Comment |
TheGreatSatan | < 20 | 3/27/2019 |
![]() |
5Y | $3.18 | -81.13% | +53.76% | +134.88 | 0 Comment | |
sikiliza | < 20 | 9/6/2019 |
![]() |
5Y | $2.39 | -74.85% | +44.95% | +119.80 | 0 Comment | |
GirlsUnder30 | < 20 | 8/13/2020 |
![]() |
5Y | $1.25 | -51.78% | +28.02% | +79.81 | 0 Comment | |
ellisrd | 44.64 | 6/8/2021 |
![]() |
5Y | $1.57 | -61.72% | +2.16% | -63.88 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.